Editor Daily Stock Deals: Re TLSA: $ 3.211.04 | 47.93%
The Bottom line - 1). Targeting 'Spike antigen' and 2). believes that it may be used as a combination therapy with previously FDA approved drugs.
Tiziana Lifesciences Develops Novel Investigational Treatment For Patients Infected with COVID-19 Utilizing Direct Delivery of Anti-Interlukin-6-Receptor Monoclonal Antibodies
Company Has Filed Patent Application in Support of Treatment of COVID-19 Utilizing Anti-IL6R Via Inhaled Delivery
NEW YORK and LONDON, April 09, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inflammatory and autoimmune diseases, announced today that it has developed investigational new technology to treat COVID-19 infections, which consists of direct delivery of anti-IL-6 receptor (anti-IL-6R) monoclonal antibodies (mAbs) into the lungs using a handheld inhaler or nebulizer. Development of this novel technology is a step forward toward expediting development of TZLS-501, a fully-human anti-interleukin-6 receptor (anti-IL6R) monoclonal antibody (mAb) for treatment of patients infected with COVID-19 (SARS-CoV-2) coronavirus. The Company believes the technology could also be applicable for use with other FDA approved mAbs and drugs. The Company has submitted a provisional patent application for the delivery technology.
“Direct delivery of anti-IL-6R mAb to the lungs using a portable handheld inhaler or nebulizer is a rapid and immediate therapy for children and adults infected with COVID-19. Importantly, this treatment with our fully human anti-IL-6R mAb (TZLS-501) has the potential to be a long-term therapy to halt progression and reduce mortality in patients with COVID-19, as a portion of the population may not opt to utilize a vaccine,” said Gabriele Cerrone, Chairman of Tiziana Lifesciences.
Patients infected with COVID-19 are known to develop an uncontrolled immune response (“cytokine storm”), which results in excessive production of pro-inflammatory cytokines and other proteins such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-a) and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), which in turn causes severe damage to lung tissue resulting in respiratory failure and eventually death. Among these cytokines, IL-6 seems to be one of the major culprits underlying coronavirus-mediated respiratory failure. Early clinical studies conducted by doctors in China suggest that anti-IL6R mAbs may be used in clinical practice for treatment of COVID-19. Consequently, China’s National Health Commission has recommended the use of Roche’s blockbuster drug, Actemra® and Sanofi’s Kevzera® for treatment of patients infected with COVID-19.
Excessive production of IL-6 is regarded as a key driver of chronic inflammation and is believed to be associated with the severe lung damage commonly observed with COVID-19 infections and acute respiratory distress syndrome (ARDS). Tiziana believes TZLS-501 (anti-IL6R) combined with this newly introduced inhalation technology may rapidly inhibit inflammation in lungs and in combination with intravenous administration may deplete circulating levels of IL-6 and potentially halt progression of COVID-19-mediated lung damage and death.
“The filing of this comprehensive provisional patent application covering treatment with our anti-IL-6R mAb, as well as prophylactic intervention with a vaccine candidate, designed from Spike (S) protein of COVID-19, is an important step in finding a solution to the current pandemic. We look forward to providing updates on the development of this product candidate and its introduction into clinical trials in a real-world setting,” said Dr. Kunwar Shailubhai, CEO & CSO of Tiziana Life Sciences.
About TZLS-501
TZLS-501, a fully human mAb, was acquired from Novimmune, a Swiss biotechnology company, in 2017. The cytokine, IL-6, a major determinant in the priming of pathogenic T cells to produce an inflammatory response, binds to its receptor subunit IL-6Rα on the cell membrane. The receptor IL-6Rα can be shed as a soluble sIL6Rα, which binds to circulating IL-6 cytokine in the blood. The downstream signaling from which sIL-6R is implicated mediates pro-inflammatory effect underlying the inflammatory diseases such as rheumatoid arthritis (RA) and acute respiratory distress syndrome (ARDS). The Company believes that the novel features of TZLS-501 consisting of its dual mechanism of action to inhibit signaling by the membrane-bound and soluble IL-6 receptor and the rapid depletion of circulating IL-6 cytokines, which is the major cause of lung damage, provides this mAb with distinct advantages for treatment of COVD-19. The Company licensed TZLS-501 from Novimmune, a Swiss biotechnology company, in 2017.
About Tiziana Life Sciences
Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. In addition to Milciclib, the Company is also developing Foralumab for liver diseases. Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (“NASH”), ulcerative colitis, multiple sclerosis, type-1 diabetes (“T1D”), Crohn’s disease, psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable.
------------
Francesca's Holdings Corporation Editor Daily Stock Deals: Re FRAN – Shorts getting squeezed
francesca's® is a specialty retailer which operates a nationwide-chain of boutiques providing customers a unique, fun and personalized shopping experience. The merchandise assortment is a diverse and balanced mix of apparel, jewelry, accessories and gifts. As of today, francesca's® operated approximately 708 boutiques in 47 states throughout the United States and the District of Columbia and also serves its customers through francescas.com. For additional information on francesca's®, please visit www.francescas.com.
---------------
Editor Daily Stock Deals: Tupperware, TUP, throwing a Big Party after reorganization and it has hired new executives – plus short covering!
$ 2.05530.5653 | 37.94%
Following months of organization design work with a leading management consulting firm, the Company's recently appointed President and Chief Executive Officer, Miguel Fernandez, has taken the first steps to execute upon the planned restructure of the Company. The new organization structure allows the Company's leadership team to acutely focus on stabilizing the core business, concentrating on its largest countries, sharing best practices across its portfolio of markets and accelerating customer and sales force acquisition and activity levels, while also improving the efficiency of all operations by separating the commercial functions from the back-office functions. This structure is intended to turnaround the financial performance of the business as Tupperware Brands develops and implements a more aggressive growth strategy in the years ahead.
The new executive hires announced today bring the necessary skills and experience to help execute the Company's turnaround plans in the near-term and its growth strategies for the long-term. Most immediately, these new leaders will make an impact by helping the organization adapt quickly to navigate the current circumstances surrounding COVID-19 and the business trends experienced in 2019.
- Patricio Cuesta has been named Executive Vice President & President, Commercial, Worldwide. In a new position for the Company, his team will be responsible for establishing and leading the global commercial focus. This work will entail integrating sales, marketing and digital strategies to support the sales growth across all markets. Cuesta's background includes the implementation of global marketing strategies at Herbalife Nutrition including product innovation, brand strategy, customer experience, sports sponsorship and global creative. Cuesta joins the Company today.
- Luis Vazquez has been named Senior Vice President, Sales & Marketing. Vazquez will lead the implementation of streamlined compensation models, enhanced customer experience, and accelerate product innovation as well as rapidly implement digital tools and increase our brand presence. He joins Tupperware Brands after holding several senior leadership roles at Herbalife Nutrition and Avon Cosmetics where he most recently served as Group Vice President, Worldwide Sales and Business Transformation. Vazquez joins the Company on April 13.
- Hector Lezama has been named Senior Vice President, Expansion & Turnaround Markets, where he will lead the implementation of turnaround strategies for identified markets in the Tupperware Brands portfolio that are positioned for growth and expansion. Lezama brings years of retail experience to the role, having formerly led the transformation of businesses and brands as CEO and President of Waldo's Holdings, and CEO of Oprimax Group as well as his work expanding several American brands into Mexico and Latin America. Lezama joined the Company on April 6.
"I am excited to welcome three seasoned executives, whom I've worked with in the past, and am confident will bring tremendous energy, experience and passion to this organization," said Mr. Fernandez. "Our new structure is designed to simplify business models, drive business growth, leverage our global infrastructure and maximize stakeholder value. Under Patricio's leadership, I am confident the shift to a commercial structure will emphasize the focus on sales growth and profitability. Now more than ever, we need to address sales trends, implement a business turnaround and reinvigorate this iconic brand."
The Company will share more information on the details of the organizational redesign, including more detail on the commercial team and functional departments, in the Company's first quarter 2020 results to be released on Wednesday, April 29, 2020.
About Tupperware Brands Corporation
Tupperware Brands Corporation, through an independent sales force of 2.9 million, is a leading global manufacturer and marketer of innovative, premium products through social selling. Product brands span several categories including design-centric food preparation, storage and serving solutions for the kitchen and home through the Tupperware brand and beauty and personal care products through the Avroy Shlain, Fuller Cosmetics, NaturCare, Nutrimetics and Nuvo brands. For more information, visit tupperwarebrands.com.
---------------
Nautilus Inc. NLS
Editor Daily Stock Deals: NLS flexing muscle! Gyms are closed and people staying and WFH, Bowflex a well-known consumer brand is in a great position to benefit from the new lifestyle
First Quarter 2020 Sales Increase by Approximately 11%, Driven by Strength of Bowflex and Schwinn Brands
Retail Segment Delivers Strong Sales Growth and Direct Segment Breaks Negative Streak
About Nautilus, Inc.
Headquartered in Vancouver, Washington, Nautilus, Inc. (NYSE: NLS) is a global technology driven fitness solutions company that believes everyone deserves a fit and healthy life. With a brand portfolio including Bowflex®, Nautilus®, Octane Fitness® and Schwinn®, Nautilus, Inc. develops innovative products to support healthy living through direct and retail channels as well as in commercial channels. Nautilus, Inc. uses the investor relations page of its website (www.nautilusinc.com/investors) to make information available to its investors and the market.
Daily Stock Deals delivering Great Deals for Smart Traders and Investors for over 10 years! Join Today for FREE and Profit from it!
